Connect With Us
Describe your need or issue with us and a Kinexum representative will be in touch with you shortly to discuss how we might be able to assist you.
Areas of expertise: Business analysis, forecasting, valuation, business development, market research
Sam Collaudin is a consultant in business strategy for drug and device biotech companies specialized in diabetes and metabolic diseases. He is currently working with different biotech companies and CMOs to help them understand diabetes patient needs, realize forecasting and prepare product launches. He is currently the CEO of Abvance therapeutics, a young biotech company that develops an innovative insulin-based treatment to reduce hypoglycemia, where he is active in the business development and investment activities. He is also an external professor at the management school of Grenoble.
Sam built a strong expertise in financial analysis and forecasting through his experiences as a consultant, as a business analyst at Adocia, but also through his activities as the chairman of a not-for-profit group of healthcare insurance companies and his previous roles as member of the governing board and the financial board of the ENS of Lyon. As chairman and effective director of an healthcare insurance company, Sam followed a specialized training in financial risk management, is strongly involved in the strategy of the company and is monitored by the French bank and insurance supervisory authority (skills, effective role in the company and reputation).
He has also a broad experience in marketing strategy, business development and business analysis, especially in the diabetes field. He realizes a daily watch of the diabetes field and of related diseases (obesity, NASH…) and publishes a quarterly synthesis of R&D news in these diseases. He has access to a strong network of top KOLs and experts. He was previously part of the business development team of Adocia with a large range of activities including a strong implication in pharmaceutical development.
By training, Sam is a researcher in biomathematics and developmental biology. He developed a good capacity to work in between different research areas, combining different skills and collaborating with different labs to solve problems. His multi-disciplinary skills allow him to have a good understanding of the current interactions between drugs, medical devices and digital health technologies. He graduated with a Ph.D. in biology (molecular and cellular biology) and biomathematics (modelling and image analysis) from the ENS of Lyon in collaboration with the university of Heidelberg and a junior MBA in biotech management from Grenoble Ecole de Management.